Protopic, Elidel Need “Black Box” Warning On Cancer Risk, FDA Cmte. Says
FDA's Pediatric Advisory Committee is recommending a "black box" warning for Novartis' Elidel and Fujisawa's Protopic based on a carcinogenicity risk with the eczema treatments
FDA's Pediatric Advisory Committee is recommending a "black box" warning for Novartis' Elidel and Fujisawa's Protopic based on a carcinogenicity risk with the eczema treatments